| - | BD patients with minor clinical manifestations (n=57) | BD patients with severe clinical manifestations (n=44) | ||
| - | % | µg/ml | % | µg/ml |
| MA (C14:0) | 0.60 (0.45-0.85) | 26.09 (15.86-32.72) | 0.80 (0.59-0.94) | 29.24 (21.87-45.71) |
| PAM (C16:0) | 22.31 (20.74-24.59) | 720.26 (647.02-952.61) | 21.78(20.56-24.62) | 916.79(732.59-1092.74) |
| STA (C18:0) | 6.11(5.32-7.62) | 213.28(156.72-276.56) | 5.92(4.86-7.27) | 227.77(174.78-329.20) |
| Total SFA | 29.42(27.14-33.22) | 959.79(832.17-1236.87) | 28.23 (25.98-31.76) | 1152.89(1011.23-1461.96) |
| POA (C16:1n-7) | 3.56 (2.18-5.02) | 101.33 (76.60-144.29) | 5.11 (3.61-6.33)** | 191.64 (159.49-252.41)** |
| OLA (C18:1n-9) | 20.15 (18.57-22.70) | 542.40 (400.92-672.51) | 22.0(20.59-27.20) | 699.96 (570.11-1043.40) |
| Total MUFA | 23.81 (21.34-27.13) | 638.50(512.01-787.02) | 27.69 (25.45 -30.62)* | 941.61(734.08-1265.42)** |
| Elongase | 0.27 (0.24-0.31) | 0.28 (0.25-0.32) | 0.27 (0.22-0.32) | 0.25 (0.21-0.31) |
| SCD-16 | 0.15 (0.09-0.21) | 0.13 (0.08-0.19) | 0.23(0.15-0.30)** | 0.21 (0.15-0.27)** |
| SCD-18 | 3.17 (2.56-4.28) | 2.48 (2.05-3.28) | 3.81(3.11-5.06) | 3.43 (2.61-3.88) |